Fosun International reported a 160.3% year-on-year surge in net profit to RMB 1.72 billion for the first half of 2026, driven by efficiency gains across its four core segments. Revenue rose 3% to RMB 86.96 billion, excluding the impact of the HAL deconsolidation, while industrial operating profit increased 17% to RMB 3.69 billion.
The Hong Kong-listed conglomerate attributed the profit growth to improved operational performance and strategic asset management. Overseas revenue climbed 5.3% to RMB 49.16 billion, representing 56.5% of total group revenue across more than 40 countries. The company’s adjusted net asset value reached RMB 128.0 billion, with a price-to-NAV ratio of 0.29 as of June 30, 2026.
The Health segment led with a 6.5% revenue increase to RMB 24.03 billion, supported by a 14% rise in innovative drug sales at Fosun Pharma. Henlius secured regulatory approvals in Canada and the EU for two products during the period. The Happiness segment reported a 6.2% revenue decline to RMB 31.63 billion, primarily due to divestments of non-core assets including Yuyuan and Lanvin Group, though core companies in the segment posted a 50% increase in operating profit.
Fosun’s Wealth segment delivered an 8.1% revenue increase to RMB 27.31 billion, with insurance subsidiaries contributing RMB 2 billion in operating profit, up 40% year-on-year. Pramerica Fosun Life Insurance reported a 52.2% premium increase to RMB 8.38 billion, while Fosun Insurance Portugal achieved a 19% premium rise to EUR 3.88 billion. Peak Re’s total premiums grew 11.8% to USD 1.19 billion, accompanied by a Moody’s rating upgrade to A3.
The Intelligent Manufacturing segment grew 14.6% to RMB 4.61 billion in revenue, with Hainan Mining’s net profit rising 83.4% to RMB 510 million, supported by lithium and oil and gas operations. The group reduced interest-bearing liabilities by RMB 4.5 billion to RMB 85.4 billion, maintaining a stable average cost of debt at 5.0%.
Fosun set a medium-term net profit target of RMB 10 billion or above and increased its dividend payout ratio target to 35%, with fiscal 2026 dividends expected to exceed HKD 1.5 billion. The company completed HKD 250 million in share buybacks during H1 2026 and extended its buyback program to March 30, 2027, with major shareholders and management intending to purchase up to HKD 500 million in additional shares.
